SEER Overview

Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.

Wall Street analysts forecast SEER stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SEER is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Seer Inc revenue for the last quarter amounts to 4.12M USD, increased 2.21

Seer Inc. EPS for the last quarter amounts to -0.32 USD, decreased -8.57

Seer Inc (SEER) has 134 emplpoyees as of March 11 2026.

Today SEER has the market capitalization of 99.86M USD.